Costs Arising from Employees’ Pension Fund Dissolution and Underfunding
First written in FY2016. 11 of 16 entries say "Restated". Latest entry: FY2022.
The whole theme swung hardest in 2021: 1 of 7 companies on the "Worse" side.
9 other companies' latest entry also says "Mitigated".
- FY2022MitigatedAnnual report
「Fiscal year ended 31 March 2022 Tokyo Pharmaceutical Industry Corporate Pension Fund Balance 16,577 Other Balance △11,438」
For the multi-employer plans, the balance for the Tokyo Pharmaceutical Industry Corporate Pension Fund improved from ¥773 million to ¥16,577 million, while the shortfall for "Other" narrowed from △¥21,487 million to △¥11,438 million. - FY2021WorsenedAnnual report
「Fiscal year ended 31 March 2021 Tokyo Pharmaceutical Industry Corporate Pension Fund Balance 773 Other Balance △21,487」
For the multi-employer plans, the balance for the "Other" pension funds was negative ¥21,487 million, and the funding shortfall widened from negative ¥18,127 million in the previous fiscal year. - FY2021-Q2RestatedAnnual report
「There were no newly arising business or other risks during the cumulative consolidated period for the second quarter. Nor were there any material changes to the business or other risks described in the securities report for the previous fiscal year.」
The company states that there have been no material changes in the risk of costs associated with the dissolution of employees' pension funds and their funding shortfalls. - FY2020-Q3RestatedAnnual report
「There were no newly arising business or other risks during the cumulative consolidated period for the third quarter. Nor were there any material changes to the business or other risks described in the securities report for the previous fiscal year.」
The company states that there have been no material changes in the risk of costs associated with the dissolution of employees' pension funds and their funding shortfalls. - FY2020-Q2RestatedAnnual report
「There were no newly arising business or other risks during the cumulative consolidated period for the second quarter. Nor were there any material changes to the business or other risks described in the securities report for the previous fiscal year.」
The company states that there have been no material changes in the risk of costs associated with the dissolution of employees' pension funds and their funding shortfalls. - FY2019-Q3RestatedAnnual report
「There were no newly arising business or other risks during the cumulative consolidated period for the third quarter. Nor were there any material changes to the business or other risks described in the securities report for the previous fiscal year.」
The company states that there have been no material changes in the risk of costs associated with the dissolution of employees' pension funds and their funding shortfalls. - FY2019-Q2RestatedAnnual report
「There were no newly arising business or other risks during the cumulative consolidated period for the second quarter. Nor were there any material changes to the business or other risks described in the securities report for the previous fiscal year.」
The company states that there have been no material changes in the risk of costs associated with the dissolution of employees' pension funds and their funding shortfalls. - FY2019-Q1RestatedAnnual report
「There were no newly arising business or other risks during the cumulative consolidated period for the first quarter. Nor were there any material changes to the business or other risks described in the securities report for the previous fiscal year.」
The company states that there have been no material changes in the risk of costs associated with the dissolution of employees' pension funds and their funding shortfalls. - FY2018MitigatedAnnual report
「The Company and its major consolidated subsidiaries have transferred to the Tokyo Pharmaceutical Industry Corporate Pension Fund, the successor plan to the Tokyo Pharmaceutical Industry Employees' Pension Fund. No additional costs are expected to arise from the return of the substitutional portion and dissolution of these employees' pension funds.」
The Osaka Pharmaceutical Industry Employees' Pension Fund was dissolved on 28 March 2018, while the Tokyo Pharmaceutical Industry Employees' Pension Fund returned its substitutional portion and transferred to a successor plan. The company states that no additional costs are expected. - FY2018-Q3RestatedAnnual report
「There were no newly arising business or other risks during the cumulative consolidated period for the third quarter. Nor were there any material changes to the business or other risks described in the securities report for the previous fiscal year.」
The company states that there have been no material changes in the risk of costs associated with the dissolution of employees' pension funds and their funding shortfalls. - FY2018-Q2RestatedAnnual report
「There were no newly arising business or other risks during the cumulative consolidated period for the second quarter. Nor were there any material changes to the business or other risks described in the securities report for the previous fiscal year.」
In the risk section, the company states that there have been no material changes in the risk of costs associated with the dissolution of employees' pension funds and their funding shortfalls. - FY2017WorsenedAnnual report
「The deficit for the Tokyo Pharmaceutical Industry Employees' Pension Fund was ¥6,243 million, while that for the Osaka Pharmaceutical Industry Employees' Pension Fund was ¥58,997 million. The provision for losses related to the dissolution of employees' pension funds was ¥319 million.」
For the multi-employer plans, the funding shortfalls of the Tokyo Pharmaceutical Industry and Osaka Pharmaceutical Industry Employees' Pension Funds were disclosed in specific monetary amounts, and the provision for losses related to the dissolution of employees' pension funds increased from ¥282 million in the previous fiscal year to ¥319 million. - FY2017-Q3RestatedAnnual report
「There were no newly arising business or other risks during the cumulative consolidated period for the third quarter. Nor were there any material changes to the business or other risks described in the securities report for the previous fiscal year.」
The company states that there have been no material changes in the risk of costs associated with the dissolution of employees' pension funds and their funding shortfalls. - FY2017-Q2RestatedAnnual report
「There were no newly arising business or other risks during the cumulative consolidated period for the second quarter. Nor were there any material changes to the business or other risks described in the securities report for the previous fiscal year.」
The company states that there have been no material changes in the risk of costs associated with the dissolution of employees' pension funds and their funding shortfalls. - FY2017-Q1RestatedAnnual report
「There were no newly arising business or other risks during the cumulative consolidated period for the first quarter. Nor were there any material changes to the business or other risks described in the securities report for the previous fiscal year.」
The company states that there have been no material changes in the risk of costs associated with the dissolution of employees' pension funds and their funding shortfalls. - FY2016First statedAnnual report
「This relates to the dissolution of the Kanto-Hokuriku-Shinetsu Pharmaceutical Industry Employees' Pension Fund, in which the consolidated subsidiary participates.」
A ¥282 million provision for losses related to the dissolution of the employees' pension fund was recorded, making the burden relating to the pension plan more concrete.